{"cluster": 20, "subcluster": 27, "abstract_summ": "Here we describe a rapid serological diagnostic assay for determining antibody receptor blocking and demonstrate the broad utility of the assay by measuring the antibody functionality of sera from small animals and non-human primates immunized with an experimental SARS-CoV-2 vaccine and using sera from infected patients.Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.We find serological antibody responses against spike are routinely elicited by infection and correlate with plasma neutralising activity and capacity to block ACE2/RBD interaction.Our results show that while cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses is rare, indicating the presence of non-neutralizing antibody response to conserved epitopes in the spike.", "title_summ": "Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patientsD614G Spike Variant Does Not Alter IgG, IgM, or IgA Spike Seroassay PerformanceCross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animalsConvergent Antibody Responses to SARS-CoV-2 Infection in Convalescent IndividualsCross-reactive antibody response between SARS-CoV-2 and SARS-CoV infectionsCross-sectional evaluation of humoral responses against SARS-CoV-2 SpikeCross-reactive antibody response between SARS-CoV-2 and SARS-CoV infectionsConvergent antibody responses to SARS-CoV-2 in convalescent individuals.", "title_abstract_phrases": "Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.Here we describe a rapid serological diagnostic assay for determining antibody receptor blocking and demonstrate the broad utility of the assay by measuring the antibody functionality of sera from small animals and non-human primates immunized with an experimental SARS-CoV-2 vaccine and using sera from infected patients.Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.Convergent antibody responses to SARS-CoV-2 in convalescent individuals.Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent IndividualsDuring the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives."}